Diagnostic biomarkers and effective therapies are urgently needed for the millions of people living with long COVID. But the challenges of designing and conducting clinical trials mean that only large, well-funded academic centres can engage with the problem.
Competing Interests
Table of Contents
J.V.W. has received a speaker fee from Pfizer, but none of the authors has a conflict of interest.